Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: May 24th, 5:22 AM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | 25.15 - 34.07 |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
Whop's study reveals one-third of Gen Z consumers regularly make purchases based on AI-generated influencer recommendations, highlighting AI influencers' rising trust and influence among young consumers on social media platforms.
Via Press Release Distribution Service · May 23, 2025
While startup headlines are often dominated by moonshot valuations and flashy funding rounds, there's a consultancy quietly turning raw potential into real money — and doing it with ruthless precision.
Via AB Newswire · May 23, 2025
Soligenix Inc. (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics
In the face of escalating antibiotic resistance, the medical community is urgently seeking alternative treatments for bacterial infections. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is at the forefront of this effort with its development of SGX943 (dusquetide), a novel broad-spectrum therapy designed to combat bacterial infections without relying on traditional antibiotics.
Via Investor Brand Network · May 23, 2025
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Progressing with FDA Clearance for Fingerprint Drug Testing as Global Demand Grows
Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, is preparing for its expected U.S. launch in 2025, as it is progressing through the FDA clearance process for its Intelligent Fingerprinting Drug Screening System. The non-invasive device, which detects recent drug use via fingerprint sweat, is gaining international traction for its speed, portability, and ability to integrate into a range of safety-critical environments.
Via Investor Brand Network · May 23, 2025
European stocks tumbled after President Trump threatened a 50% tariff on EU imports starting June 1, targeting a $250 billion trade deficit.
Via Benzinga · May 23, 2025
Nutriband Inc. (NASDAQ: NTRB) Charts Path to Commercialization
In a recent report to shareholders, Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan shared significant company achievements and milestones as well as his expectations for 2025 ( https://ibn.fm/9K5zT ). At the center of the company’s positive outlook for future is noteworthy progress made toward the commercialization of its proprietary Aversa technology, including a strong partnership with Kindeva Drug Delivery.
Via Investor Brand Network · May 22, 2025
Experts Say New Test for Brain Tumors is a Game-Changer
Researchers have developed a novel brain tumor test that surgical experts have dubbed a game changer. This is because the test collapses the needed time to obtain an accurate diagnosis to just hours rather than multiple weeks as has been the case.
Via Investor Brand Network · May 22, 2025
Columbus, GA - May 21, 2025 - In a recent case that underscores the growing concerns over unauthorized surveillance, Privin Network, a leading private investigation firm, successfully uncovered a hidden GPS tracking device during a Technical Surveillance Countermeasures ( TSCM ) sweep in Columbus, Georgia.
Via AB Newswire · May 21, 2025
Researchers Discover Potential Missing Connection Between EBV and Multiple Sclerosis
For many years, the scientific community has known that the risk of Multiple Sclerosis is markedly higher among people that have been exposed to the Epstein-Barr virus, the virus which causes infectious mononucleosis (commonly called “mono”). However, it isn’t clear why only a tiny fraction of individuals exposed to “mono” go on to develop MS.
Via Investor Brand Network · May 20, 2025
Andrew Jovic (aka Andrew Cyberkid) Expands Digital Presence with New Insights on Urban Art Collecting
Düsseldorf, Germany – May 2025 –Renowned urban and contemporary art collector Andrew Jovic, known as Andrew Cyberkid, is expanding his public presence through newly published articles and expert discussions on Medium and Reddit. Based in Düsseldorf, Jovic is internationally recognized for curating one of the most forward-thinking urban art collections in Europe.
Via GlobePRwire · May 20, 2025
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Targets Global Sales Growth with Multilingual Digital Rollout
Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, is expanding its international footprint by launching localized websites in Arabic, Italian, and Spanish. The initiative is part of the firm’s strategy to boost commercial activity across high-potential regions with growing demand for workplace safety and compliance solutions ( https://ibn.fm/odRAg ).
Via Investor Brand Network · May 20, 2025
Shares of Chinese electric vehicle battery giant Contemporary Amperex Technology Co. Ltd. (CATL) jumped 12.5% in their Hong Kong trading debut Tuesday after raising $4.6 billion in the world's largest listing this year.
Via Benzinga · May 20, 2025
PHOENIX, AZ: Infinity Paving, LLC, a leading provider of asphalt and pavement services in Phoenix and the surrounding areas, has recently earned several large paving contracts. Phoenix’s rapid expansion means that paving services are in high demand, and Infinity Paving’s newest projects include milling and repaving sections of road in Chandler and Queen Creek, repaving school tracks for local school districts, paving a new CarMax warehouse, and more.
Via GetFeatured · May 19, 2025
Soligenix Inc. (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases, recently announced its financial results for the first quarter of 2025, alongside a summary of the company’s latest accomplishments ( https://ibn.fm/OMQmM ). These milestones are representative of Soligenix’s continued commitment to advance its pipeline of therapeutic candidates, focusing on areas with significant unmet medical needs.
Via Investor Brand Network · May 19, 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names Experienced Life Science Leader as New CEO
Effective leadership is a cornerstone of organizational success, particularly in the dynamic and high-stakes realm of biotechnology. Recognizing the pivotal role of seasoned leadership, Calidi Biotherapeutics (NYSE American: CLDI) has announced the appointment of Eric Poma, PhD, as its new Chief Executive Officer and member of the board of directors ( https://ibn.fm/qMEu4 ). This strategic transition underscores Calidi’s commitment to advancing its innovative cancer therapies under experienced guidance. Dr. Poma succeeds Allan Camaisa, who will continue to serve as a board member.
Via Investor Brand Network · May 19, 2025
Greensboro, NC – Since 1974, Foreign Accents has set the standard for import vehicle care in the Triad region, providing reliable and specialized automotive repairs for European and Asian cars. Known for its technical precision and customer-first service, the shop is recognized as a top-rated auto repair shop Greensboro .
Via GetFeatured · May 16, 2025
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer
CNS Pharmaceuticals (NASDAQ: CNSP) reported a Q1 2025 net loss of $4.3 million, up from $3.5 million in the prior year period, as R&D spending increased to support data analysis for its Berubicin trial. The company remains focused on advancing TPI 287, a novel taxane with the potential to treat glioblastoma by crossing the blood-brain barrier. CNS has secured Orphan Drug Designation for TPI 287 and plans to initiate a Phase 2 study in recurrent GBM by late 2025. With $13.1 million in cash at quarter-end and an additional $5 million raised in May, the company expects to fund operations into the second half of 2026.
Via Investor Brand Network · May 16, 2025
New Multimodal AI System Boosts the Accuracy of Lung Cancer Screening
Early diagnosis of lung cancer is pivotal to effective treatment because this disease is very challenging to treat. Advances in AI are transforming the screening for this disease, improving both efficiency and accuracy. Existing screening methods such as low-dose CT have several challenges. These include high rates of false-positives and a high variability when reporting other incidental but critical information, such as findings on cardiovascular diseases.
Via Investor Brand Network · May 16, 2025
Limo SF VIP (+1-888-888-0195), a top-rated luxury transportation company, announces the launch of its elite San Francisco corporate limo service, offering a new level of reliability, comfort, and professionalism for executive travelers and corporate groups.
Via Press Release Distribution Service · May 16, 2025
SLRspeed Launches New Tools for Drifters: Low Profile Car Ramps, Toe Plates, and Drift-Spec Coilovers
Stuart, FL - May 15, 2025 - SLRspeed, a leading manufacturer of high-performance drift and suspension components, has announced the release of three critical products designed to serve grassroots drifters, competitive racers, and serious enthusiasts alike: low profile car ramps, precision toe plates , and a full line of drift-spec coilovers .
Via AB Newswire · May 15, 2025
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Strengthens Pharma Footprint Through Key Alliances
Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, is expanding its market presence and manufacturing capabilities through two new strategic partnerships. The company is collaborating with Charlotte FC to build brand visibility, particularly for its AI Tape and AVERSA(TM)—Nutriband’s proprietary technology that it believes has the potential to be the world’s first and only abuse deterrent patch platform for managing chronic pain. The company also deepened its collaboration with Kindeva Drug Delivery through an amended agreement focused on the development of Aversa(TM) Fentanyl, which combines Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. Through existing and new alliances with established brands in the health and wellness industry, Nutriband aims to diversify its revenue streams and reinforce its position as a leader in transdermal drug delivery solutions.
Via Investor Brand Network · May 15, 2025
Will Trump’s Executive Order on Drug Prices Yield the Desired Results
While President Trump signed an order aimed at reducing the high cost of prescription drugs in the U.S., it isn’t clear how exactly the price reduction will be achieved and how such reductions could impact the country in the long term.
Via Investor Brand Network · May 15, 2025
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Redtail Virotherapy Platform and Reduces Q1 Losses
Calidi Biotherapeutics (NYSE American: CLDI) reported a Q1 2025 net loss of $5.0 million, narrowing from $7.2 million in the prior year, with R&D and G&A expenses also declining. The company highlighted FDA clearance of its IND for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors, and presented promising Redtail platform data at AACR showcasing IL15 superagonist delivery via engineered oncolytic virus. Calidi also announced key leadership additions, including CEO Dr. Eric Poma and CMO Dr. Guy Clifton, as it advances systemic virotherapies targeting metastatic cancers.
Via Investor Brand Network · May 15, 2025
BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Reports Q1 Revenue of $14.5M, Expands Airtime Business Despite Healthcare Headwinds
NextPlat (NASDAQ: NXPL, NXPLW) reported Q1 2025 revenue of $14.5 million, down from $17.5 million in the prior year, driven by changes in 340B pharmacy agreements and prescription volume. Gross margin declined to 23.8%, while operating expenses fell 26% to $4.9 million due to reduced legal and non-recurring costs. Net loss narrowed to $1.3 million, or ($0.05) per share. The company ended the quarter with $17.7 million in cash and expanded its e-Commerce reach, including a 51% increase in recurring airtime revenue and growing OPKO product sales in China. Management remains focused on high-margin services and strategic healthcare growth.
Via Investor Brand Network · May 15, 2025
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Hits FDA Milestone and Expands Strategic Partnerships in Q1 Update
HeartBeam (NASDAQ: BEAT) reported Q1 2025 results highlighted by successful completion of the VALID-ECG pivotal study, supporting its 510(k) submission for 12-lead ECG synthesis software and confirming productive ongoing FDA discussions. The company launched an Early Access Program, signed a strategic partnership with AccurKardia to integrate its FDA-cleared AccurECG(TM) software, added two new U.S. patents to bring its IP total to 20, appointed CEO Robert Eno to its board, and raised $11.5 million through a public offering to support commercialization plans.
Via Investor Brand Network · May 14, 2025